Financial Review: Vital Therapies (VTL) and The Competition
Vital Therapies (NASDAQ: VTL) is one of 294 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Vital Therapies to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.
Risk & Volatility
Vital Therapies has a beta of 5.25, meaning that its share price is 425% more volatile than the S&P 500. Comparatively, Vital Therapies’ peers have a beta of 6.57, meaning that their average share price is 557% more volatile than the S&P 500.
This table compares Vital Therapies and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vital Therapies Competitors||-5,449.46%||-447.20%||-41.68%|
Earnings & Valuation
This table compares Vital Therapies and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Vital Therapies||N/A||-$45.91 million||-4.31|
|Vital Therapies Competitors||$473.33 million||$171.77 million||-7.06|
Vital Therapies’ peers have higher revenue and earnings than Vital Therapies. Vital Therapies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
25.6% of Vital Therapies shares are owned by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 32.6% of Vital Therapies shares are owned by company insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Vital Therapies and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vital Therapies Competitors||728||3173||11798||264||2.73|
Vital Therapies presently has a consensus price target of $8.00, suggesting a potential upside of 35.59%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.51%. Given Vital Therapies’ higher possible upside, equities research analysts clearly believe Vital Therapies is more favorable than its peers.
Vital Therapies peers beat Vital Therapies on 8 of the 12 factors compared.
Vital Therapies Company Profile
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.